InvestorsHub Logo
Followers 140
Posts 11663
Boards Moderated 0
Alias Born 03/15/2011

Re: bfiest post# 314576

Thursday, 10/19/2017 8:54:39 AM

Thursday, October 19, 2017 8:54:39 AM

Post# of 345706
bfiest, this is not RONIN's strategy.

I can’t believe they think they have a chance by going head to head against Ronin using Ronin’s strategy.



RONIN launched some strategy in their letters to shareholders NOT KNOWING what the PPHM strategy was (They wrote themselves that after their meeting with King and Lytle they hadn't learned of any strategy and even claimed there was not). It took several listings to find out in a detail of letter that PPHM offered to share the strategy but only under non-disclosure.

So RONIN's strategy proposition looks like no more then an educated guess of what PPHM was about to do and they probably thought they could do that too. They sold us : NO STRATEGY for something that was actually NO STRATEGY SHARED UNLESS NON-DISCLOSURE.

And of course, in another letter from RONIN to PPHM they refuse to be informed on the strategy under non-disclose again letting to believe that they have TRADING agenda's that could be crossed by such non-disclosure.

As you see from todays PR there is a clear difference between PPHM and RONIN's strategy when it comes to PS-Targeting. PPHM runs NCCN and MSK research while RONIN proposed to stop all that immediately, even before partnering, selling, licensing, etc.

For us shareholders it is important to monitor that the investment leverage (we sponsored PS-targeting) doesn't end up in private pockets (indirectly going to ES, CJ, DP, King, etc) by taking PS-Targeting PRIVATE. We must be able to buy, or in the sell get, shares of the acquiring company and stay with the PS-Targeting program.

AIMO.

Peregrine Pharmaceuticals the Microsoft of Biotechnology! All In My Opinion. I am not advising anything, nor accusing anyone.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News